Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Cerluten iconCerlutenSmall moleculeNo amino acid sequence. Icon reflects category theme only.

Cerluten

Beginner tier: 20 mg, daily · 4w on / 12w off · community consensus

CognitiveResearch
~1-3 hours half-life (estimated)·Oral

Also known as: Cytomax A-5, A-5 brain bioregulator, cerebral cortex peptide complex

Forty-eight patients. One open-label study. That is the entire human clinical record for Cerluten, a polypeptide extract from young calf cerebral cortex developed by Vladimir Khavinson in St. Petersburg. The 2003-2004 trial reported positive clinical outcomes in 64.6% of participants with TBI sequelae, post-stroke conditions, and vascular encephalopathy. Those numbers come from the same institution that sells the product. Cerluten sits in the Khavinson bioregulator family as an oral capsule option for CNS support, most often used between injectable Cortexin or Cerebrolysin courses by practitioners familiar with Russian peptide protocols.

What Is Cerluten?

Cerluten (Cytomax A-5) is a polypeptide complex extracted from calf cerebral cortex, containing low-molecular-weight peptides under 10,000 Da. The only clinical trial ever run on it showed a 64.6% positive outcome rate across 48 patients with traumatic brain injury sequelae, post-stroke states, and vascular encephalopathy at the St. Petersburg Institute of Bioregulation and Gerontology between 2003 and 2004 [1].

The extract contains low-molecular-weight peptides under 10,000 Da. Glutamic acid, aspartic acid, alanine, leucine, valine, isoleucine, proline, and serine make up the amino acid profile. Component peptides Glu-Asp-Arg and Lys-Glu-Asp stimulated serotonin expression in aging brain cortex cells in vitro by regulating the 5-tryptophan hydroxylase gene [2]. Each capsule holds 10 mg of active peptide complex.

Real-world use follows Khavinson Institute protocols: 20-40 mg per day for 10-30 day courses, repeated two to three times per year. Community data is thin. Fewer than 50 documented user reports exist across all platforms. Those who do report benefits describe subtle cognitive clarity and improved sleep, but consistently rank Cerluten below injectable Cortexin and Cerebrolysin for strength of effect.

The honest assessment: all published clinical data comes from a single institution, the same one that developed and commercializes the product. No randomized controlled trial exists. No independent replication has been published. No formal pharmacokinetic studies have been conducted. Cerluten is classified as a dietary supplement in Russia, not a registered pharmaceutical.

How Cerluten Works

Brain-derived short peptides small enough to pass through cell membranes and the nuclear envelope. That is the proposed starting point for how Cerluten works. Once inside the nucleus, these peptides are thought to interact directly with DNA and chromatin structures, influencing gene transcription without changing the underlying DNA sequence.

The best molecular data comes from studying isolated component peptides rather than the full extract. Glu-Asp-Arg and Lys-Glu-Asp stimulated serotonin expression in aging brain cortex cell cultures by regulating the 5-tryptophan hydroxylase gene through complementary binding to a specific CCTGCC nucleotide sequence [2]. This points to an epigenetic mechanism where short peptides can selectively activate gene transcription.

At the chromatin level, brain-derived short peptides have triggered selective deheterochromatinization in preclinical models [3]. That process may reactivate genes silenced during aging. The complex is also proposed to reduce neuronal apoptosis through oxidative stress pathway modulation and to balance neuroinflammatory responses.

One important distinction: most published molecular work used synthetic peptides like Cortagen (Ala-Glu-Asp-Pro), not the full Cerluten polypeptide mixture. Whether the crude extract produces the same effects as isolated sequences in a living human brain remains unconfirmed.

Cerluten Benefits

  • Cerluten benefits center on cognitive support and neuroprotection, though the evidence base is narrow and almost entirely from one research group.
  • Memory and cognitive function improvements observed in 64.6% of 48 CNS patients in the St. Petersburg open-label trial [1].
  • Component peptides Glu-Asp-Arg and Lys-Glu-Asp stimulated serotonin expression in aging brain cortex cells in vitro through 5-tryptophan hydroxylase gene regulation [2].
  • Sleep quality improvement is the most consistently reported subjective benefit across the limited community user base on Longecity forums.
  • Headache intensity reductions and improved emotional balance were documented in the clinical observation cohort during the 30-day treatment course.
  • Oral capsule format. No injections, no reconstitution, no refrigeration required during use. That alone makes it the most accessible option in the Khavinson brain bioregulator family.
  • Proposed antioxidant activity through regulation of peroxide oxidation pathways in cerebral cortex tissue, though this has only been studied in preclinical models.

Cerluten: Science vs Community Consensus

Science Only
Scientific Evidence
Weak
Based on 11 key studies·Research only

Single open-label study (n=48, developer-conducted, St. Petersburg Institute, 2003-2004) reported 64.6% positive outcomes in CNS patients (TBI sequelae, post-stroke, vascular encephalopathy), with improvements in memory, headache, emotional balance, and sleep.

Dosing studied: 20–40 mg/day oral (10–30 day courses, 2–3x per year)
Read the evidence (key study, limitations)

In vitro data shows component peptides (Glu-Asp-Arg, Lys-Glu-Asp) stimulate serotonin expression in aging brain cortex cells via 5-tryptophan hydroxylase gene regulation. No RCT, no blinding, no independent replication published.

Key Study

Khavinson VKh et al. (PMID 24738258): open-label study, 48 CNS patients, 64.6% positive outcomes; in vitro serotonin stimulation data (PMID 24909721)

Limitations

All clinical data from a single institution that developed and commercialized the product. No RCT, no blinding, no randomization, no independent replication. No formal PK/PD studies. No published human safety trials beyond the single 48-patient cohort.

Community Experience
Weak
3.5/5
Based on <50 community reports (Longecity forum + scattered blog reports)

Subtle cognitive and sleep benefits reported; consistently characterized as weaker than Cortexin (injectable) or Cerebrolysin.

Community dosing: 10–20 mg/day oral (1–2 capsules/day)
Read the reports (what users report 3, common issues 4)

Community data is extremely sparse: fewer than 50 documented user accounts across all platforms.

What users report (3)
  • Subtle cognitive clarity and reduced mental fatigue (described as helping "asthenic" conditions per Longecity)
  • Sleep quality improvement: most consistently noted subjective benefit
  • Practical: oral capsule format avoids injections
Common issues (4)
  • Effects described as subtle or weak compared to Cortexin (injectable) or Cerebrolysin
  • Evidence base limited entirely to developer-conducted studies
  • High cost (~$135–156 for 60 caps) relative to evidence quality
  • Very limited community data: difficult to distinguish effects from placebo without controls
Science-Only Evidence

Published institutional science exists (single open-label study + in vitro data) but community presence is near-zero. No meaningful community protocol data exists to compare against or diverge from. Classification reflects scientific publication without independent community validation.

Cerluten Dosage Guide

CommunityKhavinson Institute protocol
LevelDoseFrequency
Beginner20 mgDaily
Moderate40 mgDaily
Aggressive40 mgDaily
Note:

Cerluten comes as oral capsules, 10 mg each. No reconstitution math here because there's no vial to mix. That makes this one of the simplest peptides to actually use.

Standard Khavinson protocol: 2 capsules (20 mg) twice daily for 30 days. That runs through 120 capsules per course. At current pricing, a 60-capsule box costs about $156, so a full standard course at 40 mg per day will set you back roughly $312 for 120 caps. 20-cap boxes sell for $30-40, which is a better per-cap price if you're trying a mini-course first.

The mini-course option is 2 capsules once daily for 10 days. That's 20 capsules total, a reasonable way to test tolerance before committing to the full protocol.

Timing matters: take capsules 15-30 minutes before meals with water. Store at room temperature (15-25 degrees Celsius) away from light and moisture. No refrigeration needed.

One thing most beginners miss: Cerluten is considerably weaker than Cortexin (the injectable version from the same source material). If you're coming from Cerebrolysin or Cortexin and expecting similar intensity, recalibrate your expectations downward.

Cycling Protocol

On Period
4 weeks
Off Period
12 weeks

Standard Khavinson bioregulator protocol: 10-30 day courses taken 2-3 times per year with at least 3-month intervals between courses. For acute conditions, shorter 10-20 day courses with 2-3 capsules daily may be used. Some practitioners suggest pairing with Pinealon for combined CNS support.

Calculate your Cerluten dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Cerluten Protocols by Goal

beginnerClinical Trial10 days on, 6 months off; repeat 2x/year
Mini-course
Wk 1–2 (10 days)
20 mg once daily · Once daily · Oral

Expected: Subtle improvements in mental clarity and sleep quality by end of course; epigenetic effects proposed to persist several months post-course

Monitor: No blood biomarkers correlate with response. Track subjective cognitive metrics (memory, focus, sleep quality) at baseline and end of course.

How to Inject Cerluten

  1. 1
    Choose your protocol

    Mini-course: 20 mg per day for 10 days. Standard course: 40 mg per day for 30 days. Intensive: 40 mg per day for 10-20 days under physician supervision.

  2. 2
    Step 2

    For the standard course, take 2 capsules (20 mg total) in the morning, 15-30 minutes before breakfast with a full glass of water.

  3. 3
    Step 3

    Take a second dose of 2 capsules (20 mg) in the evening, 15-30 minutes before dinner. Total daily intake: 4 capsules, 40 mg.

  4. 4
    Step 4

    For the mini-course, take 2 capsules (20 mg) once daily before breakfast. Skip the evening dose.

  5. 5
    Continue for the full course length (10 or 30 days)

    Do not extend beyond 30 days per course.

  6. 6
    Step 6

    After completing the course, wait at least 3 months before repeating. Most practitioners run 2 courses per year.

  7. 7
    Track your baseline before starting

    Note sleep quality, focus, memory, headache frequency, and mood. Compare at day 15 and at course completion.

  8. 8
    Step 8

    Store capsules at 15-25 degrees Celsius in original packaging. Keep away from direct sunlight and moisture. No refrigeration required.

Cerluten Stacking Protocols

Estimated Cost

Generic / Research
~$135–$156 / 60 caps (~$2.25–$2.60/cap); ~$30–40 / 20 caps (~$1.50–2.00/cap). Full 30-day standard course at 40 mg/day (4 caps/day): ~$90–156.

Pricing updated 2026-04-09

Cerluten Side Effects

The most important thing to know about Cerluten's safety profile: it barely exists. No controlled safety trial has ever been published. No formal toxicology study. No drug interaction assessment. No reproductive toxicity data. The total documented human safety record is a single 48-patient open-label study.

In that study, no adverse effects, toxic reactions, or allergic responses were reported [1]. That sounds reassuring until you consider the sample size and the absence of systematic adverse event monitoring.

Because Cerluten is a polypeptide complex derived from bovine cerebral cortex, several theoretical concerns apply. Individual hypersensitivity reactions are possible, particularly in anyone with known sensitivity to bovine-derived products. Mild gastrointestinal discomfort could occur given the oral administration route, though this hasn't been specifically documented.

The prion question comes up frequently. Source calves are under 12 months old, which falls within the pre-prion-accumulation window. Manufacturing uses ultrafiltration below 15 kDa, and infectious PrPSc protein is 27-30 kDa. Russia has never had a major BSE outbreak. These factors substantially reduce the theoretical risk, but independent Cerluten-specific prion testing has not been published. Cortexin has a published negative immunoblot; Cerluten does not.

Batch-to-batch variability is an inherent concern with crude biological extracts. Unlike synthetic peptides with defined sequences, the exact composition of each Cerluten batch can vary. No independent purity or potency testing has been published for commercially available products.

The serotonin modulation data [2] raises a practical concern. Component peptides stimulated serotonin expression in vitro. Anyone taking SSRIs, SNRIs, or MAOIs should exercise caution. No human interaction data exists, but the mechanism is pharmacologically plausible. Discuss with a physician before combining.

Pregnancy and breastfeeding: no safety data exists. Do not use. Children under 18: insufficient pediatric data. Active malignancy: the proposed gene expression modulation mechanism creates an unfavorable risk-benefit calculation, even though harm has not been documented.

Stop use and consult a physician if you experience any allergic reaction, unexpected neurological symptoms, or gastrointestinal distress that persists beyond the first few days of a course.

Common Issues & Solutions

No noticeable effects after 30 days: Effects are subtle and epigenetic in nature: run a full standard 30-day course (40 mg/day) before concluding no response. Cognitive improvements are mild by design and may require a second course. Compare to subjective baselines tracked before starting.

Confusing Cerluten with Cortexin: These are different products. Cortexin is the injectable registered pharmaceutical (Russia) with a larger evidence base and clinically stronger effects. Cerluten is the oral supplement with lower CNS penetration and weaker documented effects. Do not substitute doses between them.

Cost vs. benefit concern: A standard 30-day course at 40 mg/day = 4 caps/day = $90–104 at current pricing. This is expensive for a supplement backed by a single developer-conducted study. Evaluate whether injectable Cortexin or Cerebrolysin offers better value for more serious CNS goals.

Prion concern: Theoretical risk is substantially mitigated: source calves are <12 months old and manufacturing uses <15 kDa ultrafiltration (infectious PrPSc is 27–30 kDa). Cerluten-specific independent prion testing has not been published (Cortexin has a published negative immunoblot; Cerluten does not). Risk is theoretical, not documented, for this product.

Active malignancy: Do not use Cerluten with active cancer without physician clearance. The proposed mechanism involves gene expression modulation in neural tissue: this is a theoretical concern, not documented harm, but the risk-benefit calculation is unfavorable.

Ask AI about this page

Ask AI for a second opinion on Cerluten dosing and side effects

Contraindications

  • Pregnancy and breastfeeding (no safety data available)
  • Known hypersensitivity to bovine-derived products or any component of the formulation
  • Children under 18 (insufficient pediatric data)
  • Active malignancy (theoretical concern with gene expression modulation)
  • Individuals with prion disease risk factors (bovine-derived tissue extract)
  • Severe allergic conditions or history of anaphylaxis to animal-derived products

Drug Interactions

  • No formal drug interaction studies have been published
  • Theoretical additive effects when combined with other neuroprotective peptides (Cortexin, Cerebrolysin, Cortagen, Semax)
  • Use caution with serotonergic medications (SSRIs, SNRIs, MAOIs) given the proposed serotonin-modulating activity of component peptides
  • May theoretically interact with CNS-active medications due to gene expression effects in neural tissue
  • No known interactions with common supplements or vitamins

Product Quality

Recommended Monitoring

TestWhenTarget
CBC with differentialBaseline + after each 10-day courseNot listed
Comprehensive metabolic panelBaseline + after first courseNot listed
Cognitive assessment (MoCA or equivalent)Baseline + every 6 monthsNot listed
CBC with differential

Monitor for immune modulation effects from bioregulator peptides

Comprehensive metabolic panel

Screen hepatic and renal function with oral peptide supplementation

Cognitive assessment (MoCA or equivalent)

Track neuroprotective endpoints: primary use case for Cerluten

Cerluten Before and After

Days 1-7

No well-documented acute effects. Based on the broader bioregulator model, gene expression changes may begin within the first week. Some users anecdotally report subtle improvements in sleep quality.

Days 8-14

Continued proposed gene modulation. In the open-label clinical study, early improvements in headache intensity and emotional balance were noted during the treatment course.

Days 15-30

Full course completion. Clinical observations suggest peak improvements in memory, cognitive function, and overall neurological status toward the end of the 30-day course.

Weeks 4-12
post-course

Effects from epigenetic remodeling and gene expression changes are proposed to persist beyond the active dosing period. The bioregulator model suggests sustained activity for several months, which is why courses are repeated only 2-3 times per year.

What to Expect

Days 1 through 7: Don't expect fireworks. No documented acute effects exist at standard doses. The bioregulator model predicts gene expression changes may begin during this window, but no pharmacokinetic data confirms it for Cerluten specifically. Some users on Longecity report subtle sleep quality improvement within the first week. Most report nothing noticeable.

Days 8 through 14: The open-label study noted early improvements in headache intensity and emotional balance during the second week. Community reports track similarly, with continued subtle sleep benefits and mild cognitive clarity. Effects remain noticeably weaker than what users report with faster-acting peptides like Semax or Selank.

Days 15 through 30: This is where the study data gets interesting. The 48-patient cohort showed peak improvements in memory, cognitive function, and overall neurological status toward the end of the 30-day course, with 64.6% showing positive outcomes. Community users who do report benefit describe it primarily as improved sleep and mild cognitive clarity. The word "subtle" appears in nearly every user report.

Weeks 4 through 16 (post-course): The Khavinson bioregulator model holds that epigenetic gene expression changes persist for months after you stop taking the capsules. That's the rationale behind the long 3-6 month rest period between courses. Mechanism data supporting this exists for related synthetic peptides like Cortagen and Epitalon, but hasn't been documented specifically for Cerluten's full polypeptide mixture. Community data on post-course persistence is insufficient to draw conclusions.

Detailed Timeline: Science vs Community

Days 1–7
Science

Bioregulator model predicts gene expression changes may begin within the first week, but no PK studies document this timeline for Cerluten specifically.

Community

Some users report subtle sleep quality improvement within the first week. Most report no noticeable acute effects.

Days 8–14
Science

Open-label study noted early improvements in headache intensity and emotional balance during the second week of the 30-day treatment course.

Community

Continued subtle sleep and mild cognitive clarity improvements reported. Effects remain subtle compared to faster-acting peptides (Semax, Selank).

Days 15–30
Science

Open-label study (n=48) documented peak improvements in memory, cognitive function, and overall neurological status toward end of the 30-day course. 64.6% of patients showed positive outcomes.

Community

Most community users who report benefit note it primarily in sleep quality and mild cognitive clarity. Effects consistently described as "subtle" compared to Cortexin or Cerebrolysin.

Weeks 4–16 (post-course)
Science

Bioregulator theory holds that epigenetic gene expression changes persist for months after the active dosing period. This is the rationale for the long 3–6 month off-period. Mechanism data exists for related synthetic peptides (Cortagen, Epitalon) but has not been specifically documented for Cerluten's full polypeptide complex.

Community

Insufficient community data to characterize post-course persistence. The long off-period is protocol-derived, not based on documented community observation of sustained benefit.

Pharmacokinetics

Half-Life
2h
Bioavailability
Oral: low, estimated <10-15% typical of unmodified short peptides; sublingual formulation may offer slightly higher absorption
Tmax
Unknown: no pharmacokinetic studies published
Data Confidence
low

Source: Estimated from general low-molecular-weight peptide kinetics; no formal PK studies published for Cerluten polypeptide complex

Pharmacokinetics: Active Dose Over Time

t½ = ~1-3 hours (estimated; no formal PK studies published)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Who Should Consider Cerluten

  • Researchers studying brain-derived peptide bioregulators and tissue-specific gene regulation
  • Individuals exploring Khavinson bioregulator protocols for cognitive and CNS support
  • Those interested in non-injection peptide options for neuroprotective research
  • Aging research subjects investigating epigenetic approaches to cognitive decline
  • Clinicians familiar with Russian peptide bioregulator protocols seeking adjunctive CNS support options

Related Peptides

What Changed for Cerluten

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 202611 Citations

References

  1. [1]Neuroprotective effects of peptides bioregulators in people of various age (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Short peptides stimulate serotonin expression in cells of brain cortex (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer's Disease (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Up to 2 years at room temperature in original sealed packaging, protected from light and moisture
After Reconstitution
N/A: oral capsule formulation does not require reconstitution
Temperature
15-25°C (59-77°F)

Frequently Asked Questions

Cortexin is the injectable bovine/porcine brain extract; a registered pharmaceutical drug in Russia with more clinical use and stronger evidence. Cerluten is the oral supplement version: far easier to use but with lower CNS penetration and weaker effects. Most practitioners use Cerluten for maintenance and Cortexin for acute neurological conditions.

Theoretical but substantially mitigated: source calves are under 12 months old (pre-prion-accumulation window), manufacturing uses <15 kDa ultrafiltration (infectious PrPSc is 27–30 kDa), and Russia has never had a major BSE outbreak. However, independent Cerluten-specific prion testing has not been published.

Standard: 2 capsules (20 mg) twice daily for 30 days, repeated 2x/year. Mini-course: 2 capsules once daily for 10 days, every 6 months. Maximum documented dose is 4 capsules (40 mg) per day under physician supervision for acute CNS conditions.

No. Cortagen (Ala-Glu-Asp-Pro) is a single synthetic tetrapeptide derived from amino acid analysis of the same cerebral cortex source material. Cerluten is a crude polypeptide complex containing many peptides up to 10,000 Da. They share a mechanistic rationale but are chemically distinct.

Yes, this is a recognized combination in the Khavinson bioregulator community. Cerebrolysin is considerably stronger with a larger evidence base; Cerluten may serve as a maintenance oral option between Cerebrolysin injection courses. No formal interaction data exists.